Current Treatment Options in Homozygous Familial Hypercholesterolemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36678563/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Relevance: We are at the dawn of a new era of effective pharmacotherapies for HoFH patients, with new agents providing an LDL-receptor independent cholesterol reduction. In this context, the present review provides a summary of the currently available therapies and emerging therapeutic agents for the management of patients with HoFH, in light...
Long-Term Prognosis of Patients with Heart Failure: Follow-Up Results of Journey HF-TR Study Population - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36680444/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Despite advances in therapeutic management of patients with heart failure, our study demonstrated that the long-term mortality still is high. Much more efforts are needed to improve the inhospital and long-term survival of patients with chronic heart failure.
Long-term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36520008/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: These data indicate that the hepatic safety of lomitapide remains favourable with no clinically significant elevations in hepatic biomarkers and hepatic stiffness remained normal for up to 9.0 years follow-up.
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions - Current Atherosclerosis Reports
Source : https://link.springer.com/article/10.1007/s11883-022-01079-7
Purpose of Review Summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2022 scientific session of the American Heart Association (AHA). Recent Findings The PROMINENT trial compared...
Summary: The late-breaking science presented at the 2022 scientific session of the AHA paves the way for future pragmatic trials and provides meaningful information to guide management strategies in cardiovascular disease prevention.
Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca2+ handling in ventricular cardiomyocytes | American Journal of Physiology-Heart and Circulatory Physiology
Source : https://journals.physiology.org/doi/abs/10.1152/ajpheart.00391.2022
Diabetic cardiomyopathy has been reported to increase the risk of fatal ventricular arrhythmia. The beneficial effects of the selective sodium-glucose co-transporter 2 inhibitor have not been fully examined in the...
Conclusion: EMPA attenuated ventricular arrhythmia inducibility by normalizing the intracellular Ca2 handling, and we speculated that this effect was, at least partly, due to the inhibition of O-GlcNAcylation via the suppression of glucose uptake into cardiomyocytes.